MedTrace Logo

Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia

NCT04190004 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-09

No results posted yet for this study

Summary

The study investigates the effect of 40IU of intranasal vasopressin on cooperative behavior in patients with schizophrenia

Conditions

Interventions

DRUG

Vasopressins

40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced

DRUG

Placebo

40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced

Sponsors & Collaborators

  • National Institute of Mental Health and Neuro Sciences, India

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04190004 on ClinicalTrials.gov